Should Baudax Bio Shareholders Vote “For” Additional Authorized Shares?

Baudax Bio, Inc.

MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX) announced that Glass Lewis & Co. has recommended that Baudax Bio shareholders vote “FOR” Proposal 3, which seeks to amend the Company’s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares.

The Annual Meeting is expected to resume with respect to Proposal 3 on June 3, 2021 at 10:00 a.m. ET and will continue to be held virtually at

Glass Lewis is widely recognized as one of the leading independent proxy voting and corporate governance advisory firms, and its recommendations are relied upon by thousands of major institutional investment firms, mutual funds and other fiduciaries throughout the United States.

In response to the favorable recommendation, Gerri Henwood, President and CEO of Baudax Bio said, “We are pleased that Glass Lewis, a highly regarded, independent, leading proxy advisory firm understands the importance of increasing the number of authorized shares to a level that allows us to achieve our corporate objectives and attract a broader and more diverse shareholder base.”

READ:  Aclaris Announces Pricing of Public Offering of Common Stock

Baudax is urging shareholders to vote as Glass Lewis recommends by voting “FOR” the proposed increase in authorized shares. Shareholders with questions may call Okapi Partners LLC at (855) 208-8902 or by email at [email protected].

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.